Natera, Inc. reported its financial results for the third quarter ended September 30, 2026. Total revenues for the quarter reached $794.0 million, representing an increase of 34.1% compared to $592.2 million in the third quarter of 2025. The company's net loss for the third quart

Natera, Inc. Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

(RTTNews) - Natera, Inc. (NTRA) reported Thursday a narrower third-quarter loss as higher testing volumes and improved average selling prices lifted revenue. The company raised its full-year revenue forecast and separately announced a CEO transition.

Natera Q3 Loss Narrows As Revenue Climbs 34%, Raises FY26 Sales Outlook; Shares Fall 16% Premarket 

Key PointsDruckenmiller owns a large stake in Natera.

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.

The average one-year price target for Natera (NASDAQGS:NTRA) (DB:45E) has been revised to $398.33 / share, an increase of 10.36% from the prior estimate of $360.94 dated September 29, 2026.These figures represent aggregate analyst targets and do not constitute a recommendation by

Natera Consensus Price Target Raised by 10.36% to $398.33

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an approximate $200.0 million dollar outflow -- that's a 1.8% decrease week over week

IBB, REGN, NTRA, ARGX: Large Outflows Detected at ETF

In recent trading, shares of Natera Inc (Symbol: NTRA) have crossed above the average analyst 12-month target price of $397.30, changing hands for $399.42/share.  When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati

NTRA Crosses Above Average Analyst Target

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Natera, Inc. News